default author photo

Ranjit Nair

University of Texas at Houston - Department of Lymphoma and Myeloma

SCHOLARLY PAPERS

2

DOWNLOADS

108

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Safety and Activity of Lenalidomide in Combination with Obinutuzumab in Patients with Relapsed Indolent Non-Hodgkin Lymphoma: A Single Group, Open-Label, Phase 1/2 Trial

Number of pages: 42 Posted: 08 Apr 2024
University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 75 (837,727)

Abstract:

Loading...

Follicular Lymphoma, B-Cell Lymphoma, Lenalidomide, Therapeutic Use, Obinutuzumab, Antineoplastic Agents, Immunological

2.

Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Number of pages: 37 Posted: 09 Nov 2022
University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma/Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 33 (1,277,121)

Abstract:

Loading...

CAR T-cell, B-cell lymphoma, Cytopenia, Interferon